A Study to Determine the Pharmacokinetic Profile of BMS-986165 Administered as Various Solid Dispersion Tablet Formulations in Healthy Subjects
Latest Information Update: 27 Dec 2019
At a glance
- Drugs Deucravacitinib (Primary) ; Famotidine
- Indications Autoimmune disorders; Crohn's disease; Inflammatory bowel diseases; Liver disorders; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Systemic lupus erythematosus; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 24 Dec 2019 Status changed from recruiting to completed.
- 25 Sep 2019 Status changed from not yet recruiting to recruiting.
- 26 Aug 2019 New trial record